{
    "nct_id": "NCT06777316",
    "official_title": "A Phase 1/2 Study of a Selective FGFR2/3 Inhibitor, CGT4859, in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors Harboring FGFR2 and/or FGFR3 Genetic Alterations",
    "inclusion_criteria": "1. Histologically confirmed locally advanced, metastatic, and/or unresectable iCCA or other solid tumor with documented FGFR2/3 alteration in blood and/or tumor.\n2. Previously treated with, not appropriate for, or declined standard-of-care first-line treatment.\n3. Have measurable disease per RECIST v1.1.\n4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n5. Have clinically acceptable local laboratory screening results (clinical chemistry and hematology) within certain limits.\n6. Resolution of toxicities from prior therapy to ≤Grade 1 (or baseline), including resolution of clinically significant laboratory abnormalities, before the first dose of study drug. Exceptions are alopecia, hypothyroidism, or type 1 diabetes mellitus controlled with medical intervention, and paronychia controlled with local intervention.\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Received chemotherapy or anticancer therapies or radiotherapy within certain timeframes before first dose of study drug.\n2. Major surgeries (eg, abdominal laparotomy) within 4 weeks of the first dose of study drug.\n3. Clinically significant corneal or retinal disorders or current evidence of retinal detachment.\n4. Received more than 2 prior FGFRi therapies\n5. Active, symptomatic, or untreated brain metastases unless the participant is clinically stable and off corticosteroids for ≥2 months.",
    "miscellaneous_criteria": "Key"
}